在PLCO参与者中使用预设的4种激肽释放酶标志物组合检测高级别前列腺癌
研究在PLCO干预组946名多族裔男性(含100名非裔美国人)的冻存血清中检测4种激肽释放酶标志物,评估其预测活检高级别前列腺癌(Gleason 7+/GG 2+)的性能。94名(10%)检出高级别前列腺癌,4种激肽释放酶组合的AUC为0.79,优于PCPTRC的0.73(提高0.060,95%CI 0.032-0.088,p<0.01);加入微精蛋白β后AUC从0.79升至0.81。
要点
- 4种激肽释放酶组合预测高级别前列腺癌AUC 0.79,优于PCPTRC的0.73。
- 加入微精蛋白β后AUC从0.79升至0.81。
- 非裔美国人中4种激肽释放酶组合AUC 0.80,优于PSA的0.67。
核心结论
- 在美国多族裔人群中,4种激肽释放酶组合对高级别前列腺癌的风险判别优于传统临床变量(年龄、PSA和直肠指检)以及PCPTRC。
研究设计与样本
- 在PLCO干预组男性的冻存血清中盲法检测游离、完整、总PSA、人激肽释放酶-2和微精蛋白β水平。
- 将946名男性(其中100名为非裔美国人)的标志物水平纳入预设统计模型,预测活检高级别前列腺癌。
主要发现
- 94名男性(10%)检出高级别前列腺癌。
- 4种激肽释放酶组合检测高级别前列腺癌的AUC为0.79,PCPTRC为0.73,提高0.060(95%CI 0.032-0.088,p<0.01)。
- 加入微精蛋白β后,AUC从0.79升至0.81。
- 非裔美国人中,4种激肽释放酶组合模型AUC 0.80,PSA为0.67。
- 以6%高级别前列腺癌风险作为活检切点时,4种激肽释放酶组合模型每1000名男性可消除420例(42%)不必要的活检,同时检出93例中的83例(88%)高级别前列腺癌。
关键数值与推荐
- 4种激肽释放酶组合预测高级别前列腺癌AUC 0.79,PCPTRC为0.73(提高0.060,95%CI 0.032-0.088,p<0.01)。
- 加入微精蛋白β后AUC从0.79升至0.81。
- 非裔美国人中4种激肽释放酶组合AUC 0.80,PSA为0.67。
- 6%高级别前列腺癌风险切点下,每1000名男性消除420例(42%)不必要的活检,检出93例中的83例(88%)高级别前列腺癌。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We assessed the performance of a 4-kallikrein panel with and without microseminoprotein-β to predict high grade (Gleason 7+/Gleason Grade Group 2+) prostate cancer on biopsy in a multiethnic cohort from PLCO (Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial). MATERIALS AND METHODS: Levels of free, intact, total prostate specific antigen, human kallikrein-2 and microseminoprotein-β were measured while blinded to outcomes in cryopreserved serum from men in the intervention arm of PLCO. Marker levels of 946 men, of whom 100 were African American, were incorporated into a prespecified statistical model to predict high grade prostate cancer on biopsy. RESULTS: The detection of high grade prostate cancer in 94 men (10%) was enhanced by the 4-kallikrein panel with an AUC of 0.79 compared to 0.73 for PCPTRC (Prostate Cancer Prevention Trial Risk Calculator), representing a 0.060 increase (95% CI 0.032-0.088, p <0.01). Additionally, the AUC increased from 0.79 to 0.81 when microseminoprotein-β was added to the 4-kallikrein panel. In African American men, the 4-kallikrein panel model also enhanced high grade prostate cancer detection over that of prostate specific antigen (AUC 0.80 vs 0.67). As an illustration of clinical implications, using 1 cutoff point for biopsy (6% risk of high grade prostate cancer) with the 4-kallikrein panel model would have eliminated unnecessary biopsies in 420 per 1,000 men (42%) while detecting high grade prostate cancer in 83 of 93 (88%). CONCLUSIONS: In a multiethnic United States population, the 4-kallikrein panel demonstrated improved risk discrimination for high grade prostate cancer over conventional clinical variables (age, prostate specific antigen and digital rectal examination) as well as PCPTRC.
引用
- Kim EH, Andriole GL, Crawford ED, et al. Detection of High Grade Prostate Cancer among PLCO Participants Using a Prespecified 4-Kallikrein Marker Panel. J Urol. 2016. PMID: 27810449. doi:10.1016/j.juro.2016.10.089
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。